Press Releases

AdvaMed Statement on Confirmation of Dr. Califf to Lead FDA

WASHINGTON, D.C. – Today, the Advanced Medical Technology Association (AdvaMed), the world’s largest trade organization representing medical technology manufacturers, released the following statements from President and CEO Scott Whitaker and Chairman of the AdvaMed Board of Directors Mike Minogue upon the confirmation of Dr. Robert Califf by the Senate as Commissioner of the Food and Drug Administration:

AdvaMed President and CEO Scott Whitaker: “We congratulate Dr. Califf on his confirmation today to once again lead FDA. His previous experience at the helm of the agency will serve him well as he hits the ground running during an ongoing global health crisis. On behalf of the medtech industry and the patients we serve, we look forward to working with the new Commissioner and his team to promote public health and continue improving patient care through innovation in life-saving medical technology. We are also deeply appreciative of Dr. Janet Woodcock’s leadership during her tenure as acting commissioner during this pandemic, and we thank her for her years of service.”

Abiomed Chairman, President, and CEO Mike Minogue, Chairman of the AdvaMed Board of Directors: “Dr. Califf’s Senate confirmation is welcome news, and I congratulate him on behalf of the medtech industry and the patients we serve. Now more than ever, FDA requires steady leadership as the country emerges from the pandemic. We look forward to working with Commissioner Califf on our common goal of ensuring that the innovative medical technologies patients and providers rely on are safe and effective.”

# # #

AdvaMed member companies produce the medical devices, diagnostic products and digital health technologies that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.